Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Bong Kyung | - |
dc.contributor.author | Lee, Youngseok | - |
dc.contributor.author | Lee, Jung Bok | - |
dc.contributor.author | Kim, Han Kyeom | - |
dc.contributor.author | Lee, Jae Bok | - |
dc.contributor.author | Cho, Su Jin | - |
dc.contributor.author | Kim, Aeree | - |
dc.date.accessioned | 2021-09-09T10:30:50Z | - |
dc.date.available | 2021-09-09T10:30:50Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2008-03 | - |
dc.identifier.issn | 1021-335X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/123928 | - |
dc.description.abstract | To evaluate the clinical significance of gene expression-based classification and define the characteristic features of the new basal-like subtype, invasive breast carcinomas were divided into ER, HER2, basal-like and null subtypes by immunohistochemical analysis. A total of 401 invasive breast carcinomas were submitted to tissue microarray and stained with ER, HER2, EGFR, c-KIT and cytokeratin (CK) 5/6. The basal-like tumors, defined as positive for one or more basal markers but negative for both ER and HER2, comprised 18.5%. They were larger (p=0.041), showed higher grade (p<0.001), and more frequently expressed p53 (p=0.003). Expression of the basal marker itself showed negative prognostic effect, particularly in node-positive group. Even ER-positive patients had far shorter disease-free survival (DFS) when the tumor coexpressed one or more basal marker (p<0.001). Discrimination of basal-like subtype or tumors positive for basal markers may be clinically significant also in the treatment and prognosis of breast carcinomas. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | GENE-EXPRESSION | - |
dc.subject | MOLECULAR CLASSIFICATION | - |
dc.subject | PROTEIN EXPRESSION | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | C-KIT | - |
dc.subject | HER-2/NEU | - |
dc.subject | SUBTYPE | - |
dc.subject | PROGNOSIS | - |
dc.subject | PROFILES | - |
dc.subject | PATTERNS | - |
dc.title | Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Youngseok | - |
dc.contributor.affiliatedAuthor | Kim, Han Kyeom | - |
dc.contributor.affiliatedAuthor | Lee, Jae Bok | - |
dc.contributor.affiliatedAuthor | Kim, Aeree | - |
dc.identifier.scopusid | 2-s2.0-40249099179 | - |
dc.identifier.wosid | 000253561400005 | - |
dc.identifier.bibliographicCitation | ONCOLOGY REPORTS, v.19, no.3, pp.617 - 625 | - |
dc.relation.isPartOf | ONCOLOGY REPORTS | - |
dc.citation.title | ONCOLOGY REPORTS | - |
dc.citation.volume | 19 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 617 | - |
dc.citation.endPage | 625 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | MOLECULAR CLASSIFICATION | - |
dc.subject.keywordPlus | PROTEIN EXPRESSION | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | C-KIT | - |
dc.subject.keywordPlus | HER-2/NEU | - |
dc.subject.keywordPlus | SUBTYPE | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | PROFILES | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.subject.keywordAuthor | basal | - |
dc.subject.keywordAuthor | breast carcinoma | - |
dc.subject.keywordAuthor | gene expression profile | - |
dc.subject.keywordAuthor | immunohistochemistry | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.